Several drug molecules have been developed in the field of Alzheimer’s disease targeting a wide variety of receptors such as G-protein coupled receptors, kinases/ enzymes, ionotropic channels, hormone receptors, etc., that largely failed during clinical trials [209]. Here, NR4A1 is linked to early-onset autosomal dominant Alzheimer disease.